Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
How do you approach HER2 directed therapy with discrepant results between FISH and Oncotype?
Especially if HER2 negative on pathological specimen
Answer from: Radiation Oncologist at Community Practice
At our institution, we don’t do Oncotype for HER2+ (by IHC or FISH) cases. See our published data showing the discrepancy.
Comments
Medical Oncologist at Stanford University, School of Medicine
Thank you so much for sharing this data!
Medical Oncologist at Joliet Oncology - Hematology Associates, Ltd.
What do you do if FISH is negative but oncotype is...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is a very rare event and we have not changed ...
3153
3158
3159
Sign in or Register to read more
7878
Related Questions
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
What are your top takeaways in Breast Cancer from ASTRO 2024?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
Thank you so much for sharing this data!
What do you do if FISH is negative but oncotype is...
This is a very rare event and we have not changed ...